Truist Reaffirms Buy on Eli Lilly (LLY) After Trial Success

Why It Matters

The trial’s mortality benefit and safety profile could expand Lilly’s insulin market share and drive earnings, making the stock attractive for growth‑oriented investors.

Key Takeaways

• Truist maintains Buy rating with $1,281 target for Eli Lilly.
• Foundayo met primary endpoint, non‑inferior to insulin glargine.
• 57% lower all‑cause mortality versus insulin glargine observed.
• No liver safety concerns across 11,000 Phase 3 participants.
• US filing planned by Q2 2026 pending FDA post‑marketing study.

Pulse Analysis

The ACHIEVE‑4 Phase 3 trial marks a pivotal moment for Eli Lilly’s diabetes pipeline. By enrolling more than 2,700 patients across 15 countries, the study not only proved Foundayo’s non‑inferiority to insulin glargine but also revealed a striking 57% cut in all‑cause deaths. Such cardiovascular and mortality advantages are rare in the insulin space, where safety and efficacy are tightly scrutinized. Coupled with a clean liver safety record across the broader Phase 3 program of over 11,000 participants, the data position Foundayo as a potentially differentiated product in a market dominated by legacy insulins.

Regulatory momentum is now the next hurdle. The company intends to file a U.S. New Drug Application by the second quarter of 2026, aligning with the FDA’s request for additional post‑marketing research to monitor rare cardiovascular events and liver outcomes. If approved, Foundayo could capture a sizable share of the $50 billion global insulin market, especially as clinicians seek therapies that offer mortality benefits. Early commercial launch in the United States would also pave the way for rapid expansion into Europe and emerging markets, where diabetes prevalence is rising sharply.

From an investment perspective, Truist’s reaffirmed Buy rating and $1,281 price target reflect confidence that the trial’s outcomes will translate into meaningful revenue growth. The diabetes franchise already contributes a substantial portion of Lilly’s earnings, and Foundayo could add a high‑margin, premium‑priced insulin line. Moreover, the positive data may spill over to other pipeline candidates, reinforcing Lilly’s reputation for innovative therapeutics. For investors, the combination of clinical upside, regulatory clarity, and a sizable addressable market underscores a compelling growth narrative.